Ruxolitinib Clinical Trials
76 recruitingDrug
Phase 246Phase 134Phase 35Phase 42Early Phase 11
Showing 1–20 of 76 trials
Recruiting
Phase 1
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell Carcinoma+22 more
Fred Hutchinson Cancer Center28 enrolled1 locationNCT05098210
Recruiting
Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled30 locationsNCT07357727
Recruiting
Phase 1
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins16 enrolled1 locationNCT07424222
Recruiting
Phase 1Phase 2
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Chronic Myelomonocytic Leukemia (CMML)Myelofibrosis (MF)
M.D. Anderson Cancer Center66 enrolled1 locationNCT07128381
Recruiting
Phase 1Phase 2
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
T-cell Prolymphocytic LeukemiaRefractory T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center36 enrolled1 locationNCT07311746
Recruiting
Phase 1
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Hematopoietic and Lymphatic System Neoplasm
City of Hope Medical Center42 enrolled1 locationNCT07025538
Recruiting
Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07359859
Recruiting
Phase 1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Neoplasms
Janssen Research & Development, LLC241 enrolled36 locationsNCT06150157
Recruiting
Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome+2 more
Jennifer Saultz51 enrolled3 locationsNCT03874052
Recruiting
Phase 1
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia
OHSU Knight Cancer Institute40 enrolled1 locationNCT07548983
Recruiting
Phase 1
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaALLALL, Childhood
University of Chicago15 enrolled2 locationsNCT03571321
Recruiting
Phase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Alopecia AreataAutoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
National Institute of Allergy and Infectious Diseases (NIAID)70 enrolled1 locationNCT05398809
Recruiting
Phase 1
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled7 locationsNCT07340138
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 1Phase 2
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin Lymphoma
Veronika Bachanova54 enrolled6 locationsNCT03681561
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 4
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Graft vs Host DiseaseChronic Graft vs. Host DiseaseCorticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals50 enrolled22 locationsNCT06824103
Recruiting
Phase 1Phase 2
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
Arkansas Children's Hospital Research Institute24 enrolled4 locationsNCT07252050
Recruiting
Phase 1
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Healthy Participants
Incyte Corporation24 enrolled1 locationNCT07588139